| Misty Blaylock, MA, CCC-SLP | |
|
1043 Brooklyn Blvd, Berea, KY 40403-1090 | |
| (859) 228-0551 | |
| Not Available |
| Full Name | Misty Blaylock |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1043 Brooklyn Blvd, Berea, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821597006 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 138621 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Misty Blaylock, MA, CCC-SLP 1013 Cherry Ct, Richmond, KY 40475-8902 Ph: () - | Misty Blaylock, MA, CCC-SLP 1043 Brooklyn Blvd, Berea, KY 40403-1090 Ph: (859) 228-0551 |
News Archive
According to the latest research new hormone therapy drugs designed to treat breast cancer may dispense with the need for chemotherapy thus avoiding the nasty side effects associated with the treatment.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
The Department of Veterans Affairs joins the Nation in observing Women's History Month in March by honoring women Veterans for their significant historical contributions and encouraging them to take advantage of the VA benefits they've earned.
Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen by three months.
Supersaturated oxygen (SSO2) administered during catheter-based treatments for heart attack can significantly reduce heart muscle damage, according to a new study reported in Circulation: Cardiovascular Interventions, a journal of the American Heart Association.
› Verified 2 days ago
Kela Parton, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 752 Richmond Rd N, Berea, KY 40403 Phone: 859-353-3666 | |
Morgan Popham, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 752 Richmond Rd N, Berea, KY 40403 Phone: 859-353-3666 | |
Christina Clark, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 524 Macrander Dr, Berea, KY 40403 Phone: 859-626-2107 | |
Michelle Lynn-hogg Raney, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 210 N Broadway St, Suite 5, Berea, KY 40403 Phone: 859-353-3666 Fax: 859-448-7077 | |
Toddler Talk: Speech-language Pathology Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 643 Sweetwater Rd, Berea, KY 40403 Phone: 606-308-5396 Fax: 606-256-9427 | |
Toni Alecia Shepherd, M.A.E.D Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 111 Legacy Dr, Berea, KY 40403 Phone: 606-224-3400 | |
Erin Brown, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 752 Richmond Rd N, Berea, KY 40403 Phone: 859-353-3666 |